Fuente: Prohibición Partners Lugar: General Market Overview



In Estonia, medical cannabis is not formally legalised under a dedicated regulatory framework but can be accessed as an unlicensed medicine through a special permit process administered by the State Agency of Medicines (SAM).



This system allows for case-by-case patient access when all other authorised treatment options have been exhausted, making Estonia’s programme one of the most restrictive and bureaucratic in Europe.



The process is designed for exceptional medical necessity and has resulted in extremely low patient numbers and no commercial medical cannabis market. There are no licensed domestic cultivators or manufacturers, and all medical cannabis products are imported on a per-patient basis following SAM approval.



Regulatory Framework



Medical cannabis in Estonia is regulated under the Medicinal Products Act and the Narcotic Drugs and Psychotropic Substances Act, which classify cannabis as a controlled narcotic substance.



While there is no general framework for medical cannabis use, the SAM can authorise the use of unlicensed medical cannabis products in special cases, following a detailed application process initiated by a prescribing specialist.



Special Permit Process:




A specialist doctor (not a general practitioner) must provide a medical justification for cannabis use, demonstrating that all licensed treatment options have been tried and failed.



The patient or prescribing doctor submits an application through a pharmacy licensed to handle narcotics.



The pharmacy applies to SAM for a permit to use an unlicensed medical cannabis product.



If SAM approves, the pharmacy orders the product from a licensed wholesaler, which must then apply for an import permit.



Once the product is imported, the pharmacy dispenses it to the patient.




This multilayered process typically takes several weeks to months and involves significant administrative hurdles, particularly as many pharmacies and distributors lack experience handling cannabis-based products.



Licensing & Oversight:



Manufacturing: Prohibited.



Oversight authority: State Agency of Medicines (SAM)



Import and wholesale: Restricted to entities licensed to handle narcotic and psychotropic substances



Cultivation: Prohibited



Patient Access



Who Can Prescribe?Only specialist doctors (such as oncologists, neurologists, or pain management physicians) can initiate an application for medical cannabis treatment. General practitioners are not authorised to prescribe cannabis.



Prescribing Requirements:




The physician must provide medical evidence and justification that all standard therapies have failed or caused intolerable side effects.



Cannabis may only be prescribed for severe and treatment-resistant conditions, often as a last resort.



Each case must be approved by SAM, and prescriptions are valid only for the specified course of treatment.




Dispensation:




Dispensing pharmacies must hold a narcotics-handling licence.



Products are imported specifically for each approved patient; no stockpiling or routine pharmacy supply is permitted.




Reimbursement:There is no public reimbursement for medical cannabis in Estonia. All treatment costs must be paid out-of-pocket by the patient.



Market and Industry




Domestic cultivation: Not permitted.



Domestic production: Not permitted.



Imports: Allowed only via SAM-approved special permits.



Products: Typically include imported extracts or oils, often sourced from Germany or the Netherlands.



Commercial activity: None — all supply operates on a patient-specific import basis.




Due to the complex access procedures and lack of streamlined supply, Estonia’s medical cannabis market remains functionally inactive, with fewer than a dozen patients reportedly accessing cannabis-based medicines annually.







Stay Informed with the Insights Hub



Cyprus medical cannabis framework continues to evolve, creating both challenges and opportunities for patients, policymakers, and businesses. To access deeper analysis, data, and market forecasts, join our Insights Hub — your gateway to industry intelligence across global cannabis markets.




Sign Up Now For Free








Market Outlook



Estonia’s medical cannabis access model is among the most conservative in Europe, reflecting the country’s historically cautious stance toward controlled substances.



For the market to develop beyond isolated patient cases, Estonia would need to:




Establish a formal medical cannabis framework within the Medicinal Products Act,



Allow for product authorisations and pharmacy stockholding, and



Enable imports through simplified procedures.




Until such reforms occur, Estonia’s medical cannabis landscape will remain limited to individual exemptions with no commercial infrastructure or measurable patient base.





















Recommended products









£1,429.00




Buy now



View cart











£1,819.00




Buy now



View cart











£2,839.00




Buy now



View cart











£1,849.00




Buy now



View cart

































The post Estonia: Medical Cannabis Market Overview 2025 appeared first on Prohibition Partners.